These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8276316)

  • 21. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
    Baek NN; Jang HR; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
    Ren Fail; 2012; 34(3):279-85. PubMed ID: 22251267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.
    Lucchi L; Ligabue G; Marietta M; Delnevo A; Malagoli M; Perrone S; Stipo L; Grandi F; Albertazzi A
    Artif Organs; 2006 Feb; 30(2):106-10. PubMed ID: 16433843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
    Usui A; Hiroura M; Kawamura M; Hibi M; Yoshida K; Murakami F; Tomita Y; Ooshima H; Murase M
    Ann Thorac Surg; 1996 Nov; 62(5):1404-11. PubMed ID: 8893576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma.
    Chen CL; Wang SD; Zeng ZY; Lin KJ; Kao ST; Tani T; Yu CK; Wang JY
    J Allergy Clin Immunol; 2006 Jul; 118(1):105-12. PubMed ID: 16815145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
    Lee YK; Lee HW; Choi KH; Kim BS
    PLoS One; 2014; 9(10):e108737. PubMed ID: 25302581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on the effects of primary therapy for DIC following circulatory arrest.
    Takemoto Y; Tanaka S; Tanabe J; Nakamura Y; Kohama A; Shibata S
    Am J Hematol; 1986 Apr; 21(4):377-82. PubMed ID: 3082185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding.
    Lee KB; Kim B; Lee YH; Yoon SJ; Kang WH; Huh W; Kim DJ; Oh HY; Kim YG
    Nephron Clin Pract; 2004; 97(1):c5-10. PubMed ID: 15153761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The individually optimized bolus dose of nadroparin is safe and effective in diabetic and nondiabetic patients with bleeding risk on hemodialysis.
    Sain M; Ljutic D; Kovacic V; Radic J; Jelicic I
    Hemodial Int; 2011 Jan; 15(1):52-62. PubMed ID: 21223482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low dose of argatroban saline flushes anticoagulation in hemodialysis patients with high risk of bleeding.
    Yixiong Z; Jianping N; Yanchao L; Siyuan D
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):440-5. PubMed ID: 19833621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient.
    Takahashi H; Muto S; Nakazawa E; Yanagiba S; Masunaga Y; Miyata Y; Tamba K; Kusano E; Matsuo M; Matsuo T; Asano Y
    Clin Nephrol; 2003 Jun; 59(6):458-62. PubMed ID: 12834179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation with micro-CT of different anticoagulation strategies during hemodialysis in patients with thrombocytopenia: A randomized crossover study.
    Vanommeslaeghe F; De Somer F; Josipovic I; Boone M; Dhondt A; Van Biesen W; Eloot S
    Artif Organs; 2019 Aug; 43(8):756-763. PubMed ID: 30820962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nafamostat mesilate reduces blood loss during open heart surgery.
    Murase M; Usui A; Tomita Y; Maeda M; Koyama T; Abe T
    Circulation; 1993 Nov; 88(5 Pt 2):II432-6. PubMed ID: 8222190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat.
    Nakamura T; Kuroda Y; Hosomi N; Okabe N; Kawai N; Tamiya T; Xi G; Keep RF; Itano T
    Acta Neurochir Suppl; 2010; 106():307-10. PubMed ID: 19812969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemodialysis using gabexate mesilate (FOY) in patients with a high bleeding risk.
    Taenaka N; Terada N; Takahashi H; Tachimori Y; Okada T; Takezawa J; Shimada Y; Yoshiya I
    Crit Care Med; 1986 May; 14(5):481-3. PubMed ID: 3084171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.
    Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N
    Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodialysis with a dialyzer loaded with argatroban may be performed in vivo without a systemic anticoagulant.
    Zhang Y; Ning J; Veeraragoo P; Li Y; Dai S
    Blood Purif; 2012; 33(4):300-6. PubMed ID: 22652560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
    Sun X; Chen Y; Xiao Q; Wang Y; Zhou J; Ma Z; Xiang J; Chen X
    Nephrol Dial Transplant; 2011 Sep; 26(9):2954-9. PubMed ID: 21303963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adsorption of nafamostat mesilate by hemodialysis membranes.
    Inagaki O; Nishian Y; Iwaki R; Nakagawa K; Takamitsu Y; Fujita Y
    Artif Organs; 1992 Dec; 16(6):553-8. PubMed ID: 1482323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.